Birinyi Associates Inc. Invests $1.48 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Birinyi Associates Inc. acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 2,075 shares of the biopharmaceutical company’s stock, valued at approximately $1,478,000. Regeneron Pharmaceuticals makes up approximately 0.4% of Birinyi Associates Inc.’s holdings, making the stock its 27th biggest position.

A number of other hedge funds also recently made changes to their positions in REGN. Worldquant Millennium Advisors LLC purchased a new position in Regeneron Pharmaceuticals in the 3rd quarter worth $127,489,000. KBC Group NV grew its stake in shares of Regeneron Pharmaceuticals by 296.7% during the fourth quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company’s stock valued at $97,338,000 after buying an additional 102,198 shares during the last quarter. Icon Wealth Advisors LLC increased its holdings in shares of Regeneron Pharmaceuticals by 18,342.0% in the third quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock worth $79,874,000 after buying an additional 75,569 shares during the period. State Street Corp lifted its stake in shares of Regeneron Pharmaceuticals by 1.3% in the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after acquiring an additional 61,277 shares during the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec lifted its stake in shares of Regeneron Pharmaceuticals by 40.2% in the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 194,625 shares of the biopharmaceutical company’s stock valued at $204,598,000 after acquiring an additional 55,828 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have commented on REGN. Wells Fargo & Company decreased their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. Barclays lowered their price target on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Bank of America reissued an “underperform” rating and issued a $565.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Oppenheimer lowered their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. Finally, Morgan Stanley dropped their target price on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $723.47 on Wednesday. The firm’s 50-day simple moving average is $698.84 and its two-hundred day simple moving average is $875.48. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $642.00 and a fifty-two week high of $1,211.20. The stock has a market cap of $79.09 billion, a PE ratio of 18.90, a price-to-earnings-growth ratio of 2.34 and a beta of 0.08. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $11.86 EPS. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be issued a dividend of $0.88 per share. The ex-dividend date is Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.49%. Regeneron Pharmaceuticals’s payout ratio is presently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.